Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylprednisolone + methotrexate + sulfasalazine + hydroxychloroquine
- Development stage
- Unknown
- Lead developer
- AIIMS New Delhi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is a treatment regimen for early rheumatoid arthritis (RA) evaluated in clinical trials by the All India Institute of Medical Sciences (AIIMS). The regimen consists of 'triple therapy' using conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)—specifically methotrexate, sulfasalazine, and hydroxychloroquine—augmented by an initial course of intravenous pulse methylprednisolone. This approach is designed to achieve rapid disease control by utilizing the potent, immediate anti-inflammatory effects of high-dose corticosteroids (the 'pulse') alongside the slower-acting but sustained immunomodulatory effects of the triple DMARD combination. The goal of such intensive early intervention is to induce remission or low disease activity more effectively than monotherapy or standard DMARD combinations alone.
- Other names
- Combination SteroidTriple DMARD therapy plus pulse methylprednisoloneAIIMS early RA regimen
02
Targets
GR (Glucocorticoid receptor)TS (Thymidylate synthase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)COX
Beyond the preview
Go deeper on methylprednisolone + methotrexate + sulfasalazine + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylprednisolone + methotrexate + sulfasalazine + hydroxychloroquine.